Monopar Therapeutics Inc (1IY0) AI Stock Analysis

0 Followers

Monopar Therapeutics Inc

(Frankfurt:1IY0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low financial leverageExtremely low leverage limits fixed financial obligations and preserves flexibility while Monopar advances its drug candidates. The sizable equity and asset base provides a stronger funding cushion than earlier periods, although continued losses could gradually reduce that support.

Negative Factors

No commercial revenueZero reported revenue means Monopar has not yet demonstrated recurring commercial demand or an operating revenue base. Until a candidate is approved and monetized, funding for research, trials, and corporate operations must come without support from established product sales.

Monopar Therapeutics Inc (1IY0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 481.46M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -30.7
Beta (1Y): 9.71
Revenue Growth: ―
EPS Growth: 35.19%
Country: Germany
Employees: 22
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Monopar Therapeutics Inc Business Overview & Revenue Model

Company Description

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNP...

Monopar Therapeutics Inc Risk Analysis

Monopar Therapeutics Inc disclosed 77 risk factors in its most recent earnings report. Monopar Therapeutics Inc reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Monopar Therapeutics Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1IY0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REPL	55Neutral	$2.21B	-7.81	-157.78%	―	―	19.12%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KURA	48Neutral	$673.43M	-2.34	-336.24%	―	-23.76%	-33.09%
CTMX	47Neutral	$431.65M	-4.72	-33.97%	―	-87.66%	-210.45%
ORIC	44Neutral	$923.55M	-6.67	-35.35%	―	―	28.64%
CADL	42Neutral	$715.45M	-6.54	-89.38%	―	―	-108.75%

* Healthcare Sector Average

Performance Comparison

DE:1IY0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1IY0	Monopar Therapeutics Inc	63.80	-4.70	-6.86%
CTMX	CytomX Therapeutics Inc.	2.13	-1.73	-44.82%
KURA	Kura Oncology	7.73	-2.95	-27.62%
REPL	Replimune Group	21.78	12.80	142.54%
ORIC	Oric Pharmaceuticals Inc	9.00	-3.19	-26.17%
CADL	Candel Therapeutics, Inc.	9.22	4.61	100.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Monopar Therapeutics Inc AI Stock Analysis